Annual FCF
-$4.18 M
+$11.86 M+73.95%
April 30, 2024
Summary
- As of February 8, 2025, IPA annual free cash flow is -$4.18 million, with the most recent change of +$11.86 million (+73.95%) on April 30, 2024.
- During the last 3 years, IPA annual FCF has fallen by -$2.63 million (-169.76%).
- IPA annual FCF is now -139186.67% below its all-time high of -$3000.00, reached on December 31, 2015.
Performance
IPA Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$1.70 M
-$171.50 K-11.26%
October 31, 2024
Summary
- As of February 8, 2025, IPA quarterly free cash flow is -$1.70 million, with the most recent change of -$171.50 thousand (-11.26%) on October 31, 2024.
- Over the past year, IPA quarterly FCF has dropped by -$171.50 thousand (-11.26%).
- IPA quarterly FCF is now -243.09% below its all-time high of $1.18 million, reached on June 30, 2005.
Performance
IPA Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$6.66 M
-$1.47 M-28.35%
October 31, 2024
Summary
- As of February 8, 2025, IPA TTM free cash flow is -$6.66 million, with the most recent change of -$1.47 million (-28.35%) on October 31, 2024.
- Over the past year, IPA TTM FCF has dropped by -$1.47 million (-28.35%).
- IPA TTM FCF is now -4002.05% below its all-time high of $170.60 thousand, reached on October 31, 2020.
Performance
IPA TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
IPA Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +74.0% | -11.3% | -28.4% |
| 3 y3 years | -169.8% | -11.3% | -28.4% |
| 5 y5 years | -43.0% | -11.3% | -28.4% |
IPA Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -169.8% | +74.0% | -654.4% | +79.0% | -84.4% | +61.6% |
| 5 y | 5-year | -183.6% | +74.0% | -592.1% | +79.0% | -4002.1% | +61.6% |
| alltime | all time | <-9999.0% | +74.0% | -243.1% | +79.0% | -4002.1% | +61.6% |
ImmunoPrecise Antibodies Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2024 | - | -$1.70 M(+11.3%) | -$6.66 M(+28.4%) |
| Jul 2024 | - | -$1.52 M(-45.4%) | -$5.19 M(+24.1%) |
| Apr 2024 | -$4.18 M(-73.9%) | -$2.79 M(+332.1%) | -$4.18 M(+15.8%) |
| Jan 2024 | - | -$646.10 K(+187.5%) | -$3.61 M(-35.9%) |
| Oct 2023 | - | -$224.70 K(-56.4%) | -$5.63 M(-33.6%) |
| Jul 2023 | - | -$515.90 K(-76.8%) | -$8.48 M(-47.1%) |
| Apr 2023 | -$16.04 M(+80.0%) | -$2.22 M(-16.6%) | -$16.04 M(+4.0%) |
| Jan 2023 | - | -$2.67 M(-13.3%) | -$15.43 M(-11.0%) |
| Oct 2022 | - | -$3.07 M(-61.9%) | -$17.33 M(+8.9%) |
| Jul 2022 | - | -$8.08 M(+401.7%) | -$15.92 M(+78.7%) |
| Apr 2022 | -$8.91 M(+475.1%) | -$1.61 M(-64.8%) | -$8.91 M(+10.3%) |
| Jan 2022 | - | -$4.57 M(+174.9%) | -$8.08 M(+85.7%) |
| Oct 2021 | - | -$1.66 M(+56.7%) | -$4.35 M(+50.8%) |
| Jul 2021 | - | -$1.06 M(+36.0%) | -$2.89 M(+86.3%) |
| Apr 2021 | -$1.55 M(+5.1%) | -$780.60 K(-7.7%) | -$1.55 M(+265.5%) |
| Jan 2021 | - | -$845.50 K(+327.7%) | -$423.80 K(-348.4%) |
| Oct 2020 | - | -$197.70 K(-171.9%) | $170.60 K(-117.9%) |
| Jul 2020 | - | $274.90 K(-20.2%) | -$953.90 K(-35.3%) |
| Apr 2020 | -$1.47 M(-49.6%) | $344.50 K(-237.2%) | -$1.47 M(-43.0%) |
| Jan 2020 | - | -$251.10 K(-81.0%) | -$2.59 M(-9.5%) |
| Oct 2019 | - | -$1.32 M(+440.3%) | -$2.86 M(-5.5%) |
| Jul 2019 | - | -$244.70 K(-68.2%) | -$3.03 M(+3.5%) |
| Apr 2019 | -$2.92 M(-0.9%) | -$768.50 K(+46.7%) | -$2.92 M(+2.9%) |
| Jan 2019 | - | -$523.70 K(-64.8%) | -$2.84 M(+4.2%) |
| Oct 2018 | - | -$1.49 M(+954.8%) | -$2.73 M(+32.8%) |
| Jul 2018 | - | -$141.20 K(-79.4%) | -$2.05 M(-30.4%) |
| Apr 2018 | -$2.95 M(+202.1%) | -$684.80 K(+66.9%) | -$2.95 M(+30.3%) |
| Jan 2018 | - | -$410.40 K(-49.7%) | -$2.26 M(+22.1%) |
| Oct 2017 | - | -$816.20 K(-21.3%) | -$1.85 M(+75.9%) |
| Jul 2017 | - | -$1.04 M(+6145.8%) | -$1.05 M(+6207.8%) |
| Apr 2017 | -$975.80 K(>+9900.0%) | - | - |
| Sep 2016 | - | -$16.60 K(-2471.4%) | -$16.70 K(+882.4%) |
| Jun 2016 | - | $700.00(-275.0%) | -$1700.00(+183.3%) |
| Mar 2016 | - | -$400.00(0.0%) | -$600.00(-79.3%) |
| Dec 2015 | -$3000.00(-90.8%) | - | - |
| Dec 2015 | - | -$400.00(-75.0%) | -$2900.00(-107.1%) |
| Sep 2015 | - | -$1600.00(-188.9%) | $40.60 K(-825.0%) |
| Jun 2015 | - | $1800.00(-166.7%) | -$5600.00(+60.0%) |
| Mar 2015 | - | -$2700.00(-106.3%) | -$3500.00(-89.3%) |
| Dec 2014 | -$32.70 K(-72.3%) | - | - |
| Dec 2014 | - | $43.10 K(-190.2%) | -$32.70 K(-90.1%) |
| Sep 2014 | - | -$47.80 K(-1325.6%) | -$329.10 K(+225.2%) |
| Jun 2014 | - | $3900.00(-112.2%) | -$101.20 K(+2.7%) |
| Mar 2014 | - | -$31.90 K(-87.4%) | -$98.50 K(-16.6%) |
| Dec 2013 | -$118.10 K(+2646.5%) | - | - |
| Dec 2013 | - | -$253.30 K(-240.6%) | -$118.10 K(-184.8%) |
| Sep 2013 | - | $180.10 K(+2628.8%) | $139.30 K(-365.3%) |
| Jun 2013 | - | $6600.00(-112.8%) | -$52.50 K(-0.2%) |
| Mar 2013 | - | -$51.50 K(-1356.1%) | -$52.60 K(+1123.3%) |
| Dec 2012 | -$4300.00(-96.9%) | - | - |
| Dec 2012 | - | $4100.00(-135.0%) | -$4300.00(-97.8%) |
| Sep 2012 | - | -$11.70 K(-280.0%) | -$197.50 K(+0.5%) |
| Jun 2012 | - | $6500.00(-303.1%) | -$196.60 K(-12.4%) |
| Mar 2012 | - | -$3200.00(-98.3%) | -$224.40 K(+60.5%) |
| Dec 2011 | -$139.80 K(-97.3%) | - | - |
| Dec 2011 | - | -$189.10 K(+1650.9%) | -$139.80 K(-97.2%) |
| Sep 2011 | - | -$10.80 K(-49.3%) | -$4.98 M(+0.4%) |
| Jun 2011 | - | -$21.30 K(-126.2%) | -$4.96 M(-0.7%) |
| Mar 2011 | - | $81.40 K(-101.6%) | -$4.99 M(-2.7%) |
| Dec 2010 | -$5.13 M(+822.5%) | - | - |
| Dec 2010 | - | -$5.02 M(<-9900.0%) | -$5.13 M(+2514.5%) |
| Sep 2010 | - | $9200.00(-116.4%) | -$196.10 K(-22.3%) |
| Jun 2010 | - | -$56.00 K(+0.7%) | -$252.40 K(-12.5%) |
| Mar 2010 | - | -$55.60 K(-40.7%) | -$288.30 K(-48.1%) |
| Dec 2009 | -$555.80 K | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2009 | - | -$93.70 K(+98.9%) | -$555.80 K(-49.6%) |
| Sep 2009 | - | -$47.10 K(-48.7%) | -$1.10 M(-34.1%) |
| Jun 2009 | - | -$91.90 K(-71.6%) | -$1.67 M(-2.7%) |
| Mar 2009 | - | -$323.10 K(-49.6%) | -$1.72 M(+18.2%) |
| Dec 2008 | -$1.46 M(+147.5%) | - | - |
| Dec 2008 | - | -$641.20 K(+3.8%) | -$1.46 M(+53.5%) |
| Sep 2008 | - | -$617.50 K(+349.1%) | -$947.60 K(+133.6%) |
| Jun 2008 | - | -$137.50 K(+133.8%) | -$405.70 K(-7.1%) |
| Mar 2008 | - | -$58.80 K(-56.1%) | -$436.90 K(-25.7%) |
| Dec 2007 | -$587.80 K(-68.6%) | - | - |
| Dec 2007 | - | -$133.80 K(+77.0%) | -$587.80 K(-32.3%) |
| Sep 2007 | - | -$75.60 K(-55.2%) | -$867.70 K(-41.3%) |
| Jun 2007 | - | -$168.70 K(-19.6%) | -$1.48 M(-21.7%) |
| Mar 2007 | - | -$209.70 K(-49.3%) | -$1.89 M(+0.9%) |
| Dec 2006 | -$1.87 M(+15.7%) | - | - |
| Dec 2006 | - | -$413.70 K(-39.7%) | -$1.87 M(-4.0%) |
| Sep 2006 | - | -$685.90 K(+18.7%) | -$1.95 M(-1.3%) |
| Jun 2006 | - | -$577.90 K(+199.6%) | -$1.97 M(+830.2%) |
| Mar 2006 | - | -$192.90 K(-60.8%) | -$212.30 K(-86.9%) |
| Dec 2005 | -$1.62 M(+122.9%) | - | - |
| Dec 2005 | - | -$492.50 K(-30.8%) | -$1.62 M(+21.8%) |
| Sep 2005 | - | -$711.60 K(-160.1%) | -$1.33 M(+41.7%) |
| Jun 2005 | - | $1.18 M(-174.2%) | -$936.60 K(-57.1%) |
| Mar 2005 | - | -$1.60 M(+688.0%) | -$2.18 M(+200.8%) |
| Dec 2004 | -$725.20 K(+132.9%) | - | - |
| Dec 2004 | - | -$202.70 K(-36.9%) | -$725.20 K(+19.1%) |
| Sep 2004 | - | -$321.30 K(+432.8%) | -$608.70 K(+39.5%) |
| Jun 2004 | - | -$60.30 K(-57.2%) | -$436.50 K(+5.6%) |
| Mar 2004 | - | -$140.90 K(+63.5%) | -$413.30 K(+32.7%) |
| Dec 2003 | -$311.40 K(+53.8%) | - | - |
| Dec 2003 | - | -$86.20 K(-42.2%) | -$311.40 K(+27.2%) |
| Sep 2003 | - | -$149.10 K(+301.9%) | -$244.90 K(+93.3%) |
| Jun 2003 | - | -$37.10 K(-4.9%) | -$126.70 K(-30.2%) |
| Mar 2003 | - | -$39.00 K(+98.0%) | -$181.40 K(-10.4%) |
| Dec 2002 | -$202.50 K(+8.5%) | - | - |
| Dec 2002 | - | -$19.70 K(-36.2%) | -$202.50 K(+22.4%) |
| Sep 2002 | - | -$30.90 K(-66.3%) | -$165.50 K(-207.6%) |
| Jun 2002 | - | -$91.80 K(+52.7%) | $153.80 K(-186.7%) |
| Mar 2002 | - | -$60.10 K(-447.4%) | -$177.40 K(-2.0%) |
| Dec 2001 | -$186.70 K(-60.9%) | - | - |
| Dec 2001 | - | $17.30 K(-94.0%) | -$181.00 K(-67.6%) |
| Sep 2001 | - | $288.40 K(-168.2%) | -$559.30 K(-39.1%) |
| Jun 2001 | - | -$423.00 K(+564.1%) | -$918.50 K(+78.8%) |
| Mar 2001 | - | -$63.70 K(-82.4%) | -$513.80 K(+7.7%) |
| Dec 2000 | -$477.20 K(+95.4%) | - | - |
| Dec 2000 | - | -$361.00 K(+409.9%) | -$477.20 K(+256.7%) |
| Sep 2000 | - | -$70.80 K(+286.9%) | -$133.80 K(-2.1%) |
| Jun 2000 | - | -$18.30 K(-32.5%) | -$136.70 K(-24.4%) |
| Mar 2000 | - | -$27.10 K(+54.0%) | -$180.80 K(-26.0%) |
| Dec 1999 | -$244.20 K(-36.6%) | - | - |
| Dec 1999 | - | -$17.60 K(-76.1%) | -$244.20 K(-39.7%) |
| Sep 1999 | - | -$73.70 K(+18.1%) | -$405.10 K(+4.1%) |
| Jun 1999 | - | -$62.40 K(-31.0%) | -$389.00 K(-3.1%) |
| Mar 1999 | - | -$90.50 K(-49.3%) | -$401.30 K(+4.3%) |
| Dec 1998 | -$384.90 K(-59.2%) | - | - |
| Dec 1998 | - | -$178.50 K(+209.9%) | -$384.90 K(+13.1%) |
| Sep 1998 | - | -$57.60 K(-22.9%) | -$340.20 K(-41.4%) |
| Jun 1998 | - | -$74.70 K(+0.8%) | -$580.50 K(-26.4%) |
| Mar 1998 | - | -$74.10 K(-44.6%) | -$789.20 K(-16.4%) |
| Dec 1997 | -$943.90 K(+104.9%) | - | - |
| Dec 1997 | - | -$133.80 K(-55.1%) | -$943.80 K(+16.5%) |
| Sep 1997 | - | -$297.90 K(+5.1%) | -$810.00 K(+58.2%) |
| Jun 1997 | - | -$283.40 K(+23.9%) | -$512.10 K(+123.9%) |
| Mar 1997 | - | -$228.70 K | -$228.70 K |
| Dec 1996 | -$460.60 K | - | - |
FAQ
- What is ImmunoPrecise Antibodies annual free cash flow?
- What is the all time high annual FCF for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies annual FCF year-on-year change?
- What is ImmunoPrecise Antibodies quarterly free cash flow?
- What is the all time high quarterly FCF for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies quarterly FCF year-on-year change?
- What is ImmunoPrecise Antibodies TTM free cash flow?
- What is the all time high TTM FCF for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies TTM FCF year-on-year change?
What is ImmunoPrecise Antibodies annual free cash flow?
The current annual FCF of IPA is -$4.18 M
What is the all time high annual FCF for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high annual free cash flow is -$3000.00
What is ImmunoPrecise Antibodies annual FCF year-on-year change?
Over the past year, IPA annual free cash flow has changed by +$11.86 M (+73.95%)
What is ImmunoPrecise Antibodies quarterly free cash flow?
The current quarterly FCF of IPA is -$1.70 M
What is the all time high quarterly FCF for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high quarterly free cash flow is $1.18 M
What is ImmunoPrecise Antibodies quarterly FCF year-on-year change?
Over the past year, IPA quarterly free cash flow has changed by -$171.50 K (-11.26%)
What is ImmunoPrecise Antibodies TTM free cash flow?
The current TTM FCF of IPA is -$6.66 M
What is the all time high TTM FCF for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high TTM free cash flow is $170.60 K
What is ImmunoPrecise Antibodies TTM FCF year-on-year change?
Over the past year, IPA TTM free cash flow has changed by -$1.47 M (-28.35%)